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Abstract 
 
 Fibroblast growth factors (FGFs) are family of proteins that belong to a group of growth 
factors that are found in mammals and play an important role in angiogenesis, differentiation, 
organogenesis, and tissue repair. In summary, their main functionality is involved in cell division 
and proliferation. Because FGFs plays such a vital role in cell proliferation, they are mainly 
involved in the process of wound healing and injuries. FGF binds to its ligand, heparin—a 
heavily sulfated glycosaminoglycan. The binding of heparin to FGF occurs through electrostatic 
interactions, specifically between the negatively charged sulfate groups on heparin and 
positively charged residues such as arginine and lysine in the heparin binding pocket of FGF.  
 FGF1, a prototype of the FGF family, has many potential applications since it is heavily 
involved in wound healing, however, FGF1 does not remain active for very long when it is not 
bound to heparin. With this in mind, this research project focuses on increasing the half-life of 
FGF1 while maintaining its stability. To achieve this objective, residue threonine at position 137, 
which is located near the heparin binding pocket was mutated to glutamic acid. Preliminary 
biophysical characterization of the mutant FGF1 protein has been discussed in this dissertation.    
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Introduction: 
 
 The human acidic fibroblast growth factor (hFGF1) is a heparin binding protein and is a 
part of a larger protein family of 23 members (1, 2). Fibroblast growth factors (FGF) play an 
exceptional role in various fundamental cellular processes in humans. Many of these cellular 
processes are activated when FGF binds to heparin and upon interaction with its cell surface 
receptor. The resulting cell signaling pathways initiate processes such as embryogenesis, cell 
proliferation and differentiation, angiogenesis, and wound healing  (2, 4, 5). Because of FGF’s 
extensive involvement in important human cellular processes, FGF has significant therapeutic 
potential, specifically for wound healing. As soon as an injury occurs, the tissue repair process 
begins by releasing growth factors, which initiate cell proliferation in the wounded area (6). 
However, despite FGFs broad involvement in critical cellular processes, it is well known for its 
instability toward thermal and proteolytic degradation (2). As a consequence, further research 
towards engineering a more robust FGF1 can pioneer new discoveries that can potentially 
improve FGF1s ability to initiate wound healing processes. Many pharmaceutical companies 
have even recognized FGF’s application as a bio-therapeutic drug candidate for wound healing, 
which has been of great interest for many researchers in this field (12).  
 The 23 members of the FGF family can be found in different organisms from nematodes 
to humans (2). These 23 FGFs have been grouped into 6 subfamilies according to their 
homology and phylogeny. It is important to note however, that FGF11-14 do not activate FGF 
receptors and are therefore not assigned to a subfamily (2, 7). Additionally, FGF15 has been 
shown to be the mouse orthologue of the human FGF19 (7). Taking FGF11-14 homologs and 
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FGF15 mouse orthologue out of consideration, there are a total of 18 mammalian fibroblast 
growth factors. The 6 FGF subfamilies are FGF1 (FGF1 and FGF2), FGF4 (FGF4, FGF5, FGF6), 
FGF7 (FGF3, FGF7, FGF10, FGF22), FGF8 (FGF8, FGF17, FGF18), FGF9 (FGF9, FGF16, FGF20), and 
FGF19 (FGF19, FGF21, FGF23) (7, 10). The subfamilies are shown in the figure below, with the 
seventh subfamily being the FGF11-14 homologs (8,10). 
 
 
 
 
 
 
 
Figure 1:  FGF subfamilies. FGF homologs are represented in the FGF11 subfamily (8). 
The FGF subfamilies were categorized based on their various functional properties, sequence 
similarities, and modes of signaling (2). The first five of the subfamilies are involved in paracrine 
signaling, which act locally, and the last subfamily (FGF19, 21, 23) is involved in endocrine 
signaling, which signal across longer distances (7,9,10).  
 All of the human FGF genes are expressed at unique sites and many are even    
differentially expressed in tissue. FGF 3,4,8,15,17,19 are expressed during embryonic 
development only, whereas FGF 1,2,5,6,7,9-14,16,18,20-23 are expressed in embryonic and 
adult tissues (2). Gene locations for all 22 FGF genes are known with the exception of FGF16. 
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There is also a variety in gene location for the human FGF genes because they are created 
through translocation and chromosomal duplication during evolution (2). The evolutionary 
history of FGF shows that human FGF and other species share about 90% of the same amino 
acid sequence, except for FGF15 (the mouse orthologue of human FGF19) (2). In general, all 
FGFs consist of 150-300 amino acids with a molecular weight ranging between 16-34 kDa (2, 
10). Crystal structures of at least one FGF member from each subfamily have been found, and 
these structures have generated further insight into the FGF protein core (10). 
 This dissertation will specifically focus on FGF1, known as human acidic FGF. The crystal 
structure of FGF1 has shown that the protein core consists of twelve antiparallel 𝜷𝜷strands 
within a conserved 𝜷𝜷 trefoil fold  (2,10). Six 𝜷𝜷 strand pairs within the 𝜷𝜷trefoil fold create a 𝜷𝜷-
barrel at the base of three of the 𝜷𝜷 strand pairs, and five of the pairs are designed as a hairpin 
structure (3, 13).  The figure below shows the structure of a biologically active human FGF1 
bound to heparin (13).  
 
 
 
 
 
 
 
Figure 2: Human FGF1 complexed to heparin oligosaccharide (13). 
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 In order for FGF1 to be biologically active, it must bind to heparin or heparan sulfate 
proteoglycans, which stabilizes FGF1 from thermal denaturation and proteolytic degradation 
(2). Heparan sulfate (HS) is a linear polysaccharide molecule that is a part of heparan sulfate 
proteoglycans (HSPG), which belongs to a family of glycosaminoglycans (14, 15).  Heparan 
sulfate glycosaminoglycans (HS-GAG) are attached to a protein core, which make up 
proteoglycans, and the proteoglycans are extruded from the cell surface into the extracellular 
space (16).  This creates a coat of HS-GAG on the cell surface, which serves as a binding region 
for growth factors, enzymes, and other signaling molecules in order to activate biological 
processes (16). HS-GAGs plays a crucial role in numerous biological processes such as cell 
growth and development, angiogenesis, anticoagulation, and viral invasion (16, 17).  
 As a linear and heterogeneous polysaccharide, HS-GAG is formed of alternating units of 
D-glucosamine (GlcN), and an iduronic acid, D-glucoronic (GlcA), to form a linear chain that can 
widely vary in length (16, 18). Figure 3 shows a disaccharide structure of both HS and heparin 
with GlcN and GlcA (22). These disaccharide units can be highly sulfonated throughout the 
chain, giving the molecule an overall negative charge (16, 18, 19).  It is also important to note 
that heparin forms an alpha helical secondary structure (27). Heparin is more heavily sulfated in 
comparison to HS (16, 19). Due to the high affinity of FGF1 towards heparin, this molecule is 
utilized as a tool to purify FGF1 through affinity chromatography (21).  
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Figure 3: Comparison of the repeating unit of heparin sulfate HS and 
heparin (disaccharide units) (22). 
 
 
 
 
 
 
 
 
Figure 4: Binding interface between heparin (in the space-filling model) FGF1 (in the dimeric form) of the FGF and cell surface 
FGF receptor (23). 
 FGF1-heparin interaction is a critical interaction preceding FGF1 receptor binding. In 
order for FGF1 to mediate its cellular response, it is necessary for it to bind to one of four 
receptor tyrosine kinases (RTK), also known as the FGF receptors (FGFRs) (24). Heparin binding 
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to FGF1 both stabilizes and protects the protein from proteolytic degradation so that it may 
then bind its FGFR (11, 24). There are four FGFRs, all of which are located on the cell surface 
and contain an extracellular, transmembrane, and intracellular domain (3).  The cytoplasmic 
domain contains the protein tyrosine kinase core and extra regulatory sequences (1, 9, 24).  
 
 
 
 
Figure 5: Depiction of the structure of FGF receptor showing the three main components: extracellular ligand-binding 
domain, the transmembrane domain, and the tyrosine kinase core (9). 
 
The extracellular ligand-binding domain contains three immunoglobulin (Ig)-like domains 
referred to as D1-D3. In between D1 and D2, there are seven to eight acidic residues that make 
up a region known as the acid box. The D2-D3 region of the receptor allows for ligand binding, 
whereas D1 and the acid box play roles in auto inhibition (7, 24).  
 
 
 
 
 
 
Figure 6: Structural modules (D1-D3) present in the extracellular domain of the FGF receptor. (7). 
The three immunoglobulin domains of RTKs are alternatively spliced to create several isoforms 
of FGFRs (7, 24).  Alternative splicing occurs particularly in FGFR1-3 genes coding for the D3 
segment, in which exons 8 and 9 form two additional forms of FGFR (11,24). FGFR4 does not 
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partake in alternative splicing. These additional FGFR isoforms exhibit unique specificity for FGF 
ligand binding (11, 24). Figure 7 shows how the alternative splicing process occurs. Exon 7 
encodes for the N-terminal of D3, which is also termed ‘a.’ Exons 8 and 9 encode for the C-
terminal of D3, and they are referred to as ‘b’ and ‘c’ forms (24). 
 
Figure 7: Alternative splicing sites in the D3 domain of FGFR to form additional isoforms of FGFR. (24). 
Since FGFR1-3 are all involved in alternative splicing and each FGFR forms two additional 
isoforms termed as ‘b’ and ‘c’, there would be a total of seven FGFR isoforms, including FGFR4 
(24).  All 23 FGFs have varying ligand-binding affinity towards specific FGFR isoforms. The table 
below shows ligand specificities for each FGFR isoform. One significant characteristic of FGF1 
that further lends towards its therapeutic potential is its ability to bind to all FGFR isoforms. 
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Table 1: Ligand binding specificties of the different FGFR isoforms 
FGFR Isoform FGF Ligand Specificity 
FGFR1b FGF1, 2, 3, 10 
FGFR1c FGF1, 2, 4, 5, 6 
FGFR2b FGF1, 3, 7, 10, 22 
FGFR2c FGF1, 2, 4, 6, 9, 17, 18 
FGFR3b FGF1, 9 
FGFR3c FGF1, 2, 4, 8, 9, 17, 18, 23 
FGFR4 FGF1, 2, 4, 6, 8, 9, 16, 17, 18, 19 
  
 Once the FGF1-heparin complex binds to the D2-D3 region of the FGFR, the receptor 
dimerizes. FGFR dimerization initiates autophosphorylation of seven tyrosines in the protein 
tyrosine kinase (PTK) domain of the FGFR, thus activating various signaling pathways (7, 9, 25). 
In addition to the phosphorylation of the tyrosines, there are several regulatory sequences 
extending at the cytoplasmic PTK domain that allow for docking proteins to bind (24).  In 
particular, the juxtamembrane region, which is longer than many RTKs, functions as a binding 
region for the phosphotyrosine binding (PTB) domain of FGFR substrate 2, also referred to as 
FRS2 (7, 9, 24). FRS2 serves as a family of docking proteins and includes FRS2𝛼𝛼 and FRS2𝛽𝛽. 
When FRS2 is phosphorylated, two signaling pathways are activated, mitogen activated protein 
kinase (MAPK) and phosphoinositide 3-kinase-Akt  (AKT) (7, 9, 24). Phospholipase C (PLC) 𝛾𝛾 1, is 
also a docking protein which activates a specific signaling pathway (9, 26). Furthermore, one 
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particular intracellular tyrosine, Y766, when phosphorylated near the C-terminal, creates a 
binding region specific for the SH2 domain of PLC �  (9, 24). Once phosphorylated, activated 
PLC 𝛾𝛾 stimulates hydrolysis of phosphatidylinositol generating diacylglycerol (DAG) and Inositol 
triphosphate (IP3) as secondary messengers (24). All together, the four key signaling pathways 
are, mitogen activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K/AKT), 
phospholipase C 𝛾𝛾 (PLC 𝛾𝛾), and Janus kinase (JAK STAT) (9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Panel-A,FGF receptor showing D1-D3, the transmembrane domain, and the catalytic domain with the protein 
tyrosine kinase core. Panel- B, Dimerization of FGFR resulting in activation of the following four main signaling pathways. 
MAPK, PI3K, PLC 𝜸𝜸, and JAK STAT (9).  
 
As mentioned, FGF1 has the ability to bind to all seven isoforms. This characteristic makes it of 
great interest in this research lab as well as in other clinical studies. FGF1 is made up of 154 
amino acids; however, a truncated form of FGF1 consisting of 140 amino acids is used in 
Kumar’s lab in order to eliminate degradation products (often produced from the first 14 amino 
  14 
terminal residues) (20).  Although this truncated form is shorter, it is still demonstrated to have 
full functionality. As mentioned earlier, FGF1 on its own is rather unstable. Under physiological 
conditions, nearly 50% of FGF1 is unfolded, which makes the protein more susceptible to 
proteases and difficult to use for medical applications such as wound healing agent, or 
composition in cosmetic application(s) etc. (20). Previous mutagenic research in the heparin-
binding region of FGF1 has generated more robust forms of FGF1 with increased half-life and 
stability. Residues in the heparin binding region of FGF1 are largely positively charged arginines 
and lysines (27). Thus the interaction between heparin and FGF1 is mainly governed by 
electrostatic forces. Figure 9 below shows the heparin-binding region of FGF1. Specifically, 
heparin-binding residues are N32, K126, K127, K132, K142, R133, 
and R136.  
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Heparin-binding region of FGF1 bound to heparin. The heparin binding residues are also labeled on this figure. 
 
Previous research in the Kumar lab generated an R136E-FGF1 mutant where arginine at 
position 136 was replaced with a glutamic acid. Characterization of this R136E-FGF1 mutant 
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revealed decreased affinity for heparin, increased thermal stability and drastically increased cell 
proliferation activity. One of the neighboring residues of R136 is threonine at position 137, 
shown in figure 10. T137 will be the focus of this research project. Threonine, a polar amino 
acid, will be mutated to glutamic acid, a negatively charged amino acid with a longer side chain. 
Introduction of a glutamic acid at this position is predicted to generate repulsive electrostatic 
interactions that may reduce the affinity of FGF1 towards heparin molecule.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: R136 and its neighboring residue T137, which has been mutated to E137. 
 
 
T137 
R133 
R136 
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Experimental Methods and Materials 
 
Bacterial Transformation of T137E-FGF1: 
 
 Mutant T137E- FGF1 plasmid DNA was generated using Quick Change site directed 
mutagenesis kit as per the manufacturer instructions. Two types of expression hosts BL-21 
(DE3) and BL-21 star Escherichia coli (E. coli) competent cells were transformed with T137E 
plasmid. Transformed BL-21(DE3) and star cells were selected on agar plates containing 
100µg/ml of ampicillin (AMP) as a selection marker. Transformation was completed using the 
heat shock technique according to protocol well established in the Kumar lab.  
 
Small Scale Expression (SSE) of T137E-FGF1: 
 
 SSE of T137E-FGF1 protein was performed to verify the presence of the mutant protein 
in the cells and the ability of these cells to produce the desired protein. This is accomplished by 
growing cells overnight in lysogeny broth (LB) at 37°C and inoculating fresh LB the next morning 
with the overnight culture.  After approximately 2 hours, the optical density (OD) of the culture 
was checked using UV-visible spectroscopy at a wavelength of 600 nm. E. coli cells replicate 
approximately every 20 minutes; therefore growth curve hits an exponential rate in the log 
phase at an OD between 0.4-0.6.  
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 When the culture had reached the desired OD, it is induced with Isopropyl 𝛽𝛽-D-1-
thiogalactopyranoside (IPTG), which activates the lac operon in order to induce rapid protein 
expression. Four hours later, cells were harvested. The cell culture is then lysed using 
ultrasonication, which releases cytosol content into solution. The cell debris is separated from 
solution—which contains our protein of interest—using high-speed centrifugation at 19000x 
rpm for 30 minutes. Samples of the culture are taken pre-induction, post induction, and from 
the insoluble pellet and supernatant following centrifugation. These samples were resolved on 
sodium dodecyl sulfate poly acrylamide gel electrophoresis (SDS-PAGE) to monitor protein 
expression.  
 
Large Scale Expression (LSE) of T137E-FGF1: 
 
 LSE was performed to generate large quantities of T137E-FGF1 so that the protein may 
be purified for characterization studies. This expression follows the same protocol as SSE except 
with larger quantities of autoclaved LB media.  1 mL of glycerol stock of T137E-FGF1 and AMP 
(100µg/ml) was added to a starter flask and was incubated over night at 37oC with 250rpm. The 
next day, fresh, sterile LB was inoculated with the overnight culture and AMP and incubated at 
37°C. At OD the culture was induced with IPTG and harvested 4 hours later using high-speed 
centrifugation.  After centrifugation, the clear broth was discarded and the bacterial cell pellet 
containing the protein of interest was stored at -20°C.  
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Purification of T137E-FGF1: 
 
 Purification of WTFGF1 and T137E-FGF1 was performed using affinity chromatography 
on a 20 mL heparin sepharose column. The pellet obtained from LSE was thawed and 
resuspended in 25 mL of 10 mM phosphate buffer containing 10 mM NaCl at pH 7.2. The cells 
were lysed using ultra sonication and the clear lysate was separated from cell debris by 
centrifugation at 19,000 rpm for 30 minutes.  Immediately after the centrifugation, the 
supernatant was separated and loaded onto the pre-equilibrated heparin sepharose column. A 
smear of the pellet was collected for analysis via SDS-PAGE.  
 After loading, the supernatant was incubated on the column for 30 minutes to insure 
ligand binding.  The protein was then purified of contaminant proteins by washing the column 
with 10 mM phosphate buffer (PB) at pH 7.2 containing increasing salt gradients.  All washes 
were collected and samples from each wash were prepared with trichloroacetic acid (TCA) 
precipitation protocols for SDS-PAGE analysis. The purity of the protein was verified from the 
SDS-PAGE gel represented by a distinct band weighing 16kDa. The pure protein fraction 
collected at 1,500 mM NaCl was then buffer exchanged to 100mM NaCl and concentrated using 
a Millipore centrifugal concentrator with a 10kDa molecular weight cutoff. The concentration of 
the protein was measured using a NanoDrop at A280 nm.  
 Similar purification strategy was employed for BL-21 Star expression host. These cells 
are known to contain less proteolytic enzymes and were therefore predicted to increase 
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protein yield. In addition, protease inhibitors, phenylmethanesulfonyl fluoride (PMSF) and 
ethylenediaminetetraacetic acid (EDTA), were added to each wash buffer. Lastly, 25 mM 
ammonium sulfate (AS) was added to each wash buffer in order stabilize T137E-FGF1 and to 
avoid protein aggregation. Unfortunately analysis of protein elute via SDS-PAGE, still revealed 
the presence of multiple lower weight bands in addition to at 16KDa protein band. To 
determine whether the additional bands were degradation products or contaminants, the 
protein fraction was dialyzed into 100 mM NaCl/25 mM AS/10mM PB at pH 7.2. The dialyzed 
protein was then concentrated and characterized with biophysical techniques. 
 
 
Intrinsic Fluorescence Spectroscopy of T137E-FGF1:  
 
 Intrinsic fluorescence spectroscopy was performed of T137E-FGF1 and WTFGF1 with 
and without heparin to assess any changes in structure and folding of the protein using a 
Hitachi F-2500 spectrofluorometer. The samples for this experiment were prepared using a 
protein concentration of 0.1 mg/mL in 10 mM PB which contained 100 mM NaCl, pH 7.2. All of 
the samples were excited at a wavelength of 280 nm, while the data was collected between 300 
and 450 nm in order to analyze the fluorescence of tyrosine at 308 nm and tryptophan at 350 
nm.  
 
 8-Anilinonaphthalene-1-sulfonic acid (ANS) Binding Assay of T137E-FGF1: 
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 ANS binding was performed to analyze any conformational changes in WTFGF1 & 
T137E-FGF1 with and without heparin using a Hitachi F-2500 spectrofluorometer.  ANS is a 
hydrophobic probe that binds to pockets of hydrophobic residues and gives information on how 
well the protein is folded. The excitation wavelength was set to 380 nm, and the emission 
wavelength range was between 450-600 nm because ANS fluoresces with an emission maxima 
at around 500 nm. Samples were prepared by diluting the protein to 15 μM, and an ANS stock 
solution was also prepared that allowed the addition of 1 μL of stock ANS to the protein 
sample. Adding 1 μL of the stock ANS into the protein allows the ANS concentration to increase 
by 20 μM. The relative fluorescence intensity (RFI) was recorded until the ANS concentration 
reach 400 μM. Data was plotted with concentration of ANS on X-axis against ANS  
 
Far UV Circular Dichroism (CD) Spectroscopy of T137E-FGF1: 
  
 Far UV CD spectroscopy was utilized to assess the secondary structure of T137E-FGF1 in 
comparison to WTFGF1 with and without heparin using a JASCO 1500 CD spectrometer. A 
quartz cell of 0.2 mm path-length was loaded with 100 µL of T137E-FGF1 protein sample. The 
data was scanned between a wavelength range of 190-250 nm and with 3 accumulation scans. 
Once collected, the data was smoothed and the buffer signal was appropriately subtracted. 
These steps were repeated additionally in order to collect data of the samples with heparin.  
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Molecular Dynamics Simulation of T137E-FGF1: 
 
 A T137E mutant file of FGF1 was created from the WTFGF1 protein data bank structure 
1RG8 (13). Molecular dynamic simulations of T137E-FGF1 were run using this base file. The 
protein was solvated after the structure of T137E had been minimalized which left a minimum 
distance of 10 Å between the protein and solvent box edge. After neutralizing the system with 
NaCl, the effective salt concentration was set to 0.150 M. The structure was prepared for 
production runs by subjecting the system to numerous refinement steps in order to relax the 
side chains, backbone, and the molecules and ions from the surrounding water. The isothermal-
isobaric (NPT) ensemble was used to equilibrate the system along with NAMD 2.9 and the 
CHARMM36 forcefield.  
Using Langevin dynamics, the temperature was maintained at 300 K along with a damping 
coefficient of 1 ps-1. The Langevin piston method was used to maintain a constant pressure of 1 
atm, period of 100 fs, and a decay time of 50 fs. Next, the particle mesh Ewald method with 
periodic boundary conditions was utilized in order to measure long-range electrostatic 
interactions. Once these interactions were computed, switching functions beginning at 10 Å 
were used to cut off electrostatic and Van der Waals interactions beyond a distance of 12 Å, 
and all of the hydrogen bonds were maintained rigid. The simulation time step was set to 1fs.  
 Minimization of the side-chains required 10,000 steps, while the backbone atoms were 
fixed as water and ions were not present. Following the side-chain minimization, the protein 
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structure was solvated. Fixing all of the protein atoms and subjecting the system to 1,500 steps 
of minimization and 50 ps of dynamics relaxed the water molecules around the protein. To 
further relax the solvent system, harmonic constraints with a force constant of 1 kcal/ (mol Å2) 
were utilized on the protein atoms. A gradual increase in temperature from 0 K to 300 K at a 
rate of 10K per 2ps was completed before running the production followed by 250 ps of 
dynamics.  Based upon the leveling of RMSD and energy fluctuations, production run 
preparedness was determined.  
 The stability of the protein domains and protein-protein complexes was determined 
with 50 and 100 ns simulations. For the production runs, a 2 fs time step was used, while the 
remaining parameters were the same as the last 250 ps from the final equilibration run. The 
RMSD trajectory tool, visualized simulations, and the C- α measured distances from VMD, were 
used to evaluate backbone RMSDs. VMD was also used to collect simulations for hydrogen 
bonding, solvent accessible surface area (SASA), and the gyration radius.  
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Results and Discussion: 
 
Expression and Purification of WTFGF1 
 
 Figure 11 is the SDS PAGE analysis of the purification of WTFGF1. The expression and 
purification of WTFGF1 was successfully verified from lane 5 with a distinct thick band.  
 
 
 
 
 
 
 
 
Expression and purification of T137E-
FGF1  
  
 Figure 
12 is an SDS PAGE analysis of a purification of T137E-FGF1 expressed in BL-21(DE3) cells (the first 
cell line used for the over expression of the protein). Lane 6 is the protein elute in 1500mM NaCl 
represented by a 16KDa band. However, there is also a band above and below the band of 
interest. The band above could be a possible contaminant protein, while the band below could 
be either a contaminant or a degradation product. The protein yield from purification was less 
                           1            2           3                       4             5                        6 
Figure 11: SDS PAGE analysis of the purification of WTFGF1. The represented lanes are Pellet 
(Lane-1), Supernatant (Lane-2), 100 mM NaCl (Lane-3), 800 mM NaCl (Lane-4), 1500 mM NaCl 
(Lane-5),  Protein Marker (Lane-6). This gel shows that WTFGF1 has been  successfully expressed 
and purified as there is a thick band in lane 5 at 1500 mM NaCl.  
kDa 
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than 1 mg from a liter of bacterial culture which is very low compared to that of WTFGF1 
approximately 60mgs (data not shown) 
 
 
 
 
Figure 12: SDS PAGE analysis of purification of T137E-FGF1 expressed BL-21 (DE3) cells using a heparin sepharose column. 
The represented lanes are Protein Marker (Lane-1), Pellet (Lane-2), Supernatant (Lane-3), 500 mM NaCl/10 mM PB  (Lane-4), 
800 mM NaCl/10 mM PB (Lane-5), 1,500 mM NaCl/10 mM PB (Lane-6), Urea (Lane-7). In Lane-6, a band corresponding to 16 
kDa size represents the presence of T137E-FGF1, however there are additional contaminant or degradation bands that are 
also present.  
 Additional purifications were also performed to collect pure protein, however, 
contaminant or degradation bands were still present. Due to the difficulty in collecting pure 
protein, another cell line, BL-21 Star, was transformed with T137E-FGF1 plasmid. This cell line 
was used specifically because it has fewer proteolytic enzymes. Following transformation, a 
small-scale expression was performed to verify the presence of T137E-FGF1. Figure 13 
represents an SDS PAGE analysis of this small-scale expression. The different lanes represent 
snapshots of the growth phases throughout the expression. Lane 4 in particular is significant 
because it shows a band verifying a successful transformation. The first two lanes are T137E-
FGF1 content of the cells before and after induction with IPTG. The third lane is 14kDa lysozyme 
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used as a marker, and the fourth and fifth lanes are the supernatant and pellet following 
harvest, sonication, and centrifugation of the cells. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 13: SDS PAGE analysis of a small-scale expression of T137E using BL-21 Star cells. The represented lanes are, Un-
induced (Lane-1),Induced (Lane-2),  Lysozyme (14 kDa protein molecular weight marker) (Lane-3),  Supernatant (Lane-4),  
Pellet (Lane-5). Overall, this gel shows snapshots of the culture growth along the expression. Lane 2, the induced sample was 
triggered with Isopropyl B D-1-thiogalactopyranoside (IPTG), which mimics the lac operon in order to trigger protein 
expression at a high rate. Successful transformation and growth of T137E is verified from the band in Lane 4.  
 
 Once the transformation and growth of T137E-FGF1 was verified, purification was 
performed to obtain pure T137E-FGF1. The buffers used in this purification were modified in 
comparison to the previous purification buffers. In addition to the 10 mM phosphate and 
varying amounts of NaCl, 25 mM ammonium sulfate was added to the buffers as another 
source of salt to stabilize the protein. In addition, protease inhibitors were also added to all of 
the buffers to prevent any proteolytic degradation that may occur from proteolytic enzymes 
released into solution following sonication. Phenylmethylsulfonyl fluoride (PMSF), an inhibitor 
that specifically targets serine proteases (28, 29) and ethylenediaminetetraacetic acid (EDTA), a 
chelating agent, which can inhibit metalloid proteases were both added to the buffers (30). 
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Figure 14 shows the SDS PAGE analysis of the purification of T137E-FGF1 expressed in BL-21 
Star, and purified with modified buffers. Lane 7 shows a band of T137E-FGF1 weighing 16kDa. 
However, there are additional bands below T137E-FGF1 confirming that T137E-FGF1 is not 
pure. The additional bands could be due to degradation or protein contaminant bands. The 
protein yield from this purification was approximately 0.5mgs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14:  SDS PAGE analysis of the purification fractions of T137E-FGF1 using BL-21 Star as the cell line and modified 
buffers. The represented lanes are Pellet  (Lane-1), Supernatant (Lane-2), 100 mM NaCl/25 mM AS/ 10 mM PB (Lane-3), 400 
mM NaCl/25 mM AS/ 10 mM PB (Lane-4), 500 mM NaCl/25 mM AS/ 10 mM PB (Lane-5), 800 mM NaCl/25 mM AS/ 10 mM PB 
(Lane-6), 1500 mM NaCl/25 mM AS/ 10 mM PB (Lane-7), Lysozyme (14 kDa) (Lane-8), Urea (Lane-9). Lane-7 of this gel 
presents a band matching to 16 kDa, representing T137E-FGF1, however there are also protein contaminant or degradation 
bands below that even after utilizing a new less cell line with less proteolytic enzymes and buffers with protease inhibitors. 
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 Following several rounds of purification, concentrated samples of T137E-FGF1 from 
both BL-21(DE3) and BL-21 Star purifications were collected. These concentrated samples were 
analyzed on an SDS PAGE gel along with a WTFGF1 sample, shown in figure 15. This was 
performed to compare the two T137E-FGF1 samples with the WTFGF. Looking at lanes 2 and 3, 
the T137E-FGF1 bands from BL-21(DE3) and BL-21 Star, respectively, can be seen matching up 
with the single WTFGF1 band in lane 1. Once again, this verifies the presence of T137E-FGF1, 
however, lanes 2 and 3 both show multiple bands above and below the band of interest, which 
represent possible contamination and degradation respectively. It is concluded that the 
utilization of a second cell line with ammonium sulfate and proteolytic inhibitors does not 
eliminate degradation or contamination bands.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: SDS PAGE analysis of WTFGF1 and two different samples of T137E-FGF1. The represented lanes are WTFGF1 (Lane-
1), T137E (DE3 cell line) (Lane-2), T137E (Star cell line) (Lane-3). This gel shows T137E-FGF1 bands aligned with the WTFGF1 
band. However, degradation or contamination bands are still present under both T137E-FGF1 bands. 
     1                                      2                                        3 
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Biophysical Characterization of T137E-FGF1 
 
Effect of mutation on surface hydrophobicity of FGF1: 
 
 An ANS binding assay was completed to assess the structure and folding of T137E-FGF1 
in the absence and presence of heparin. ANS is used as a probe to access conformational 
changes in protein structure upon ligand binding. The fluorescent properties of ANS differ when 
bound to hydrophobic residues. Therefore, the relative fluorescent intensity of ANS is 
representative of the amount of hydrophobic residues exposed in T137E-FGF1 in the absence 
and presence of heparin. Figure 16 is a graph of the ANS binding assay of T137E-FGF1 and 
WTFGF1 with and without heparin. Comparing the mutant with the wild type, this data shows 
that there is not a significant difference in intensity, thus the structure and folding of the 
mutant does not seem to be compromised.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: ANS binding to T137E-FGF1 and WTFGF1 in the presence and absence of heparin. It is appears that both the 
mutant and wild type have similar ANS binding affinity, suggesting that the structure and folding of T137E-FGF1 has not 
significantly changed. 
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Effect of mutation on folding of FGF1: 
  
 Intrinsic fluorescence spectroscopy was performed to analyze the changes occurring in 
the tertiary structure of T137E-FGF1 in comparison to WTFGF1 (figures 17 and 18). Figure 17 is  
the fluorescence data of the mutant from the cell line BL21 (DE3). This data shows that T137E-
FGF1 has a very small peak at 308 nm, exposing tyrosine, in comparison to the WTFGF with a  
larger peak at 308 nm. This could be due to the small protein yield collected from the BL21 
(DE3) cell line.  
Figure 17: Intrinsic fluorescence of T137E FGF1 and WTFGF1 in the presence and absence of heparin (using BL21 (DE3) cell 
line).  
 
In figure 18, the spectra of T137E-FGF1 displays a very high intensity around 350 nm compared 
to WTFGF1, which characteristically shows a peak only at 308nm representative of tyrosine 
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fluorescence. This large peak of T137E-FGF1 reveals a completely exposed tryptophan 
indicating that the mutant is not folded in the same manner as WTFGF1.  
 
Figure 18: intrinsic fluorescence depicting the folding of T137E-FGF1 mutant shows a major peak at 350 nm, suggesting that 
T137E-FGF1 mutation causes the complete exposure of the lone tryptophan in the protein.  
 
Effect of mutation on secondary structure of FGF1:  
 An additional experiment was performed to investigate the mutant’s secondary 
structure by utilizing far-UV Circular Dichroism (CD) as a probe. Figure 19 shows the CD data of 
both T137E-FGF1 and WTFGF1 with and without heparin. The spectra of WTFGF1 shows a 
positive peak in the region spanning from 240-220nm, which is representative of the β –trefoil 
motif. However, the mutant spectra is drastically different and represents the secondary 
structure similar to that of an alpha helix. This important finding confirms that the bands 
present above and below the desired mutant protein band in the SDS PAGE gels of figure 4 are 
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indeed contaminant bands. Because FGF1 is composed of beta strands arranged in beta barrel, 
the alpha helical nature of the mutant spectra is due to other contaminant proteins present in 
the sample. 
 
Figure 19:  Far-UV CD spectra of T137E FGF1and WTFGF1 in the presence and absence of heparin.  
 
 
PyMOL, a molecular visualization program, was utilized to look further into the location and 
surroundings of T137. The PyMOL image of T137-FGF1, figure 20, exhibits that the functional 
group of threonine, a hydroxyl, is facing the hydrophobic core of the protein. Considering that 
threonine is a polar amino acid, this was an interesting discovery. Furthermore, it was found 
that the hydroxyl group of threonine was hydrogen bonded with several residues within 5 Å 
distance around that hydrophobic core. The following residues were a part of this hydrogen-
bonding network with threonine: glycine at position 134 (G134), phenylalanine at position 122 
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(F122), and asparagine at position 120 (N120). Glycine is an amphipathic molecule, meaning 
that it contains a non-polar end as well as a polar end. Phenylalanine is a non-polar molecule, 
while asparagine is a polar molecule. These three residues are all within 3 Å from the threonine. 
The significance of this hydrogen-bonding network is that T137 is very important for stabilizing 
the hydrophobic core as well as the heparin-binding region.  In particular, T137 is stabilizing two 
important loops that are in the heparin-binding pocket. Since T137 was mutated with E137, it 
was predicted that the heparin-binding region and the hydrophobic core would be severely 
disrupted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: PyMOL image of FGF-1 showing the hydrogen-bonding network created by T137. T137 is hydrogen-bonded with 
G134, F144, and N120. 
R133  
& R136 
F122 
N120 
G13
 
 
 
T13
 
 
  33 
The following PyMOL image, figure 21, displays the mutation, E137. As predicted, this image 
shows loop disruption around the heparin binding region. The functional group of glutamic acid 
is shown on the outer surface of the protein, as it is a polar amino acid. However, as the amino 
acid is shifted outwards away from the hydrophobic core where the threonine was located, the 
hydrogen-bonding network with G134, F122, and N120, is completely disrupted. In fact, these 
residues are within 11 Å in distance from the glutamic acid, compared to being within 3 Å in 
distance from the threonine. The loop disruption caused by the mutation interrupted the 
heparin binding region by unfolding it. 
 
Figure 21: PyMOL image of FGF1 E137. This structure shows that the hydrogen-bonding network has been disrupted due to 
replacement of threonine with glutamic acid at position 137.  
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N120 
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Conclusions:  
 
 
 After several purifications of T137E-FGF1, it was concluded that homogeneous form of 
T137E-FGF1 is very difficult to obtain due to the inherent instability of the protein molecule 
generated because of the exposed loop from the disruption in hydrogen bonds. Initially, BL-21 
(DE3) cell line was used to perform a bacterial transformation and move further in obtaining 
pure T137E-FGF1 via protein purification. The first purification of T137E-FGF1 using the BL-21 
(DE3) cell line showed that there was very low expression of the protein. Comparing this to the 
purification of T137E-FGF1 using the BL-21 Star cell line, BL-21(DE3) showed less contamination 
with similar yields. This can be exemplified from the intrinsic fluorescence data of T137E-FGF1 
performed using the protein obtained through expression in the BL-21(DE3) cell line. Intrinsic 
fluorescence was also performed using T137E-FGF1 from the BL-21 Star cell line. The data was 
significantly different compared to the previous cell line because it showed that T137E-FGF1 
was completely unfolded due to tryptophan being entirely exposed at 350 nm. Additionally, CD 
data of T137E-FGF1 using the BL-21 Star cell line showed that the mutant had an alpha helical 
secondary structure whereas WTFGF1 is a beta barrel. From these preliminary characterization 
experiments, it was concluded that overexpression of the protein in BL-21(DE3) cells produces 
lower yields of the mutant protein but interestingly results in the presence of lesser protein 
contaminants.  BL-21 Star, on the other hand, results in slightly higher protein yield.  However, 
the presence of higher amounts of contaminating protein products hampered the unambiguous 
characterization of the mutant protein.  
 The core of this project is based on the mutation from threonine to glutamic acid in 
order to introduce a negative charge in the heparin binding region of FGF1 and analyze the 
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effects it can have on heparin binding to FGF1. It was very evident that introducing a glutamic 
acid in place of threonine caused a drastic change in the folding of the heparin binding region. 
The hydrogen bonds that threonine shared with several residues in the hydrophobic core of the 
heparin binding region of FGF1 were severely disrupted when it was replaced with glutamic 
acid. This disruption in the hydrogen-bonding network appears to cause the heparin binding 
loop to significantly unfold and be exposed to the solvent. This conclusion is also consistent 
with increased susceptibility of the mutant protein to proteolytic degradation resulting in the 
appearance of several degradation bands on the SDS PAGE.  
 Although pure T137E-FGF1 was not obtained, the overall findings of this project 
highlight the critical role of T137 in the maintenance of the structural integrity of FGF1.  
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